Meeting
2015 ASCO Annual Meeting
Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
Authors
Atsushi Ohtsu
National Cancer Center Hospital East, Kashiwa, Japan
Atsushi Ohtsu , Takayuki Yoshino , Mona M. Wahba , Fabio M. Benedetti , Robert J. Mayer , Eric Van Cutsem
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01607957
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3564)
DOI
10.1200/jco.2015.33.15_suppl.3564
Abstract #
3564
Poster Bd #
56
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
First Author: Atsushi Ohtsu
Poster
2023 ASCO Annual Meeting
Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.
First Author: Arvind Dasari
Poster
2016 Gastrointestinal Cancers Symposium
TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase 3 RECOURSE trial.
First Author: Robert J. Mayer
Poster
2023 ASCO Annual Meeting
Matching-adjusted indirect treatment comparisons (MAIC) of sotorasib vs trifluridine/tipiracil (T/T) and regorafenib as monotherapy in chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price